Skolkovo and Promomed will create components for new medicines

17.06.2022

Industry development

The Skolkovo Foundation and the Promomed Group of companies have agreed on joint projects in the field of biotechnology, molecular modeling, and the creation of new dosage forms and components for them. The cooperation agreement was signed within the framework of the St. Petersburg International Economic Forum, the press service of the foundation reported on Friday.


"A new era in medicine has arrived — biotechnologies, RNA therapy, and top-quality domestic substances are the answer to the challenges of the time. We will answer them together with the leader of innovation, the Skolkovo Foundation. We see great prospects in joint work on modeling candidate molecules for medicines, developing methods for synthesizing pharmaceutical substances, optimizing and improving production technologies for APIS and finished dosage forms, and in other areas," said Peter Bely, Chairman of the Board of Directors of Promomed Group of Companies, quoted in the message.

According to the foundation, a research and development center (R&D center) may be established on the basis of the Mordovia Technopark to develop cooperation. Its tasks will include conducting and coordinating preclinical and clinical studies necessary for the further commercialization of the products being developed. According to Igor Drozdov, Chairman of the Board of the Skolkovo Foundation, the project will help Russia achieve import independence in the field of creating domestic medicines.

"One of the priorities of the state program for the Development of the Pharmaceutical and medical industry is import independence. This task is "Skolkovo" It aims to cooperate with leading domestic pharmaceutical companies. We are confident that the partner center based on our regional operator in Mordovia will benefit in the creation of medicines for the residents of our country," Drozdov emphasized.



About companies

Skolkovo, Russia's largest innovation center, plays a significant role in strengthening the foundation of the national economy. In 2021, the revenue of Skolkovo residents increased by almost 55% compared to 2020 and amounted to 247.8 billion rubles. As of May 1, 2022, the number of Skolkovo resident startups has exceeded 3,300. The number of jobs in the ecosystem is rapidly approaching 70,000.


Promomed Group of Companies is a Russian pharmaceutical company engaged in the development, production and promotion of medicines. Promomed's portfolio includes more than 200 names of medicines, 80% of which are included in the list of vital and essential. Promomed's developments are aimed at fighting infections, and are also used to treat oncological, neurological, and endocrinological diseases. The company is working on the formation of a special anti-covid portfolio. Now it is represented by products such as Esperavir, Areplivir, Enoparin, Radamine Viro and others.

Source: www.tass.ru

Sources
  1. https://tass.ru/obschestvo/14949343

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office